Skip to Content
Morningstar

Alnylam Pharmaceuticals Inc ALNY

Morningstar Rating
Unlock
Stock XNAS Rating as of
$247.61 +4.29 (1.76%)
View Full Chart
As of Delayed Price Pre-Open: $249.99 +2.37
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Alnylam: Shares Soar on Positive Phase 3 Results for Vutrisiran; Raising Fair Value Estimate

Rachel Elfman

Narrow-moat Alnylam announced positive top-line results from the HELIOS-B Phase 3 study of its investigational RNAi therapeutic, vutrisiran, to treat patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM). Investors reacted quite favorably to the good news and have sent the stock up over 40%. We have raised our fair value estimate to $223 per share from $199 due to an increased probability of approval of 85% for this pipeline candidate based on the positive clinical trial results.

Read Full Report

Price vs Fair Value

View History
ALNY is trading at a 799% premium.
Price
$247.61
Fair Value
$138.00
Uncertainty
High
1-Star Price
$892.63
5-Star Price
$228.30
Economic Moat
Rlcgbf
Capital Allocation
Brtklyxwh

Bulls Say, Bears Say

Bulls

Alnylam's Nobel-prize-winning technology and massive intellectual property in RNA interference helped the firm create an entirely new class of therapeutics for difficult to treat diseases.

Bears

Alnylam's valuation rests on its ability to maintain six-figure pricing and payers' willingness to continue reimbursement, which could be affected by shifts in healthcare drug policy.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALNY is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$243.32
Day Range
$242.08–250.11
52-Week Range
$141.98–252.87
Bid/Ask
$243.46 / $249.99
Market Cap
$31.32 Bil
Volume/Avg
56 / 911,650

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
15.50
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Growth
Total Number of Employees
2,100
Website
https://www.alnylam.com

Competitors

Valuation

View More
Metric
ALNY
IONS
INCY
Price/Earnings (Normalized)
 ——15.56
Price/Book Value
 —22.202.46
Price/Sales
 15.508.363.55
Price/Cash Flow
 145.44—17.04
Price/Earnings
ALNY
IONS
INCY

Financial Strength

Metric
ALNY
IONS
INCY
Quick Ratio
 2.866.753.29
Current Ratio
 3.177.373.47
Interest Coverage
 −2.38−3.53333.13
Quick Ratio
ALNY
IONS
INCY

Profitability

Metric
ALNY
IONS
INCY
Return on Assets (Normalized)
 −2.47%−9.42%13.25%
Return on Equity (Normalized)
 —−71.60%17.32%
Return on Invested Capital (Normalized)
 −7.00%−11.55%14.51%
Return on Assets
ALNY
IONS
INCY
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
JvycqxqxwHym$636.9 Bil
 Vertex Pharmaceuticals Inc
VRTX
NgbxtlndGvzst$122.3 Bil
 Regeneron Pharmaceuticals Inc
REGN
YjwxlyzRvvzdxq$115.1 Bil
 Moderna Inc
MRNA
GfjkqlnbtRxlc$44.9 Bil
 argenx SE ADR
ARGX
HxpfzmmgPfgr$26.2 Bil
 BioNTech SE ADR
BNTX
StmvwrqCcwn$19.0 Bil
 Biomarin Pharmaceutical Inc
BMRN
PrygxtchYzklcz$15.6 Bil
 United Therapeutics Corp
UTHR
XnjsjlsxSxczt$14.1 Bil
 Royalty Pharma PLC Class A
RPRX
MswrgjgbTyzhyz$11.7 Bil

Sponsor Center